Login to Your Account

Layoffs at Alnylam to Follow Sunset of Novartis Partnership

By Catherine Shaffer

Monday, September 27, 2010
Novartis AG has declined a $100 million option to extend its landmark partnership with Alnylam Pharmaceuticals Inc. for the development of new RNAi therapeutics, a deal once valued at up to $700 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription